EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective
Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.664
https://www.valueinhealthjournal.com/article/S1098-3015(24)00779-4/fulltext
Title :
EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00779-4&doi=10.1016/j.jval.2024.03.664
First page :
Section Title :
Open access? :
No
Section Order :
10138